Written by: Alyson Leonard, PharmD, BCPS, BCOP, Cone Health
Download Here

Osimertinib is an indicated and preferred first line treatment option for patients with Epidermal Growth Factor Receptor (EGFR) gene mutation positive Non-Small Cell Lung Cancer (NSCLC) with Exon 19 deletion and exon 21 L858R.This PQI aims to provide guidance for initiating therapy with osimertinib. Continue reading Osimertinib (Tagrisso®) in EGFR Positive Non-Small Cell Lung Cancer

Read More

Written by: Jeff Engle, PharmD, MS
Download Here

This PQI will discuss effective management of adverse effects of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma and discuss data supporting the sequencing of patients to second-line therapy with regorafenib for increased survival benefit.

Continue reading Sorafenib (Nexavar) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

Read More